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Background: The increasing availability of generic drugs (GD) resulted in a remarkable reduction in treatment costs
that allowed a better access to health care.The aim of this study is to evaluate the share of anti-asthmatic generic
drugs during the period 1999-2010 in Morocco and to look at the factors influencing generic development.
Methods: In this study, we used Moroccan sales data from IMS Health (Intercontinental Marketing Services). The
consumption of the drugs was expressed in DDD/1000 inhabitants/day according to the WHO ATC/DDD methodology.
Results: Between 1999 and 2010, anti-asthmatic consumption increased from 3.91 to 14.43 DDD/1000 inhabitants/day.
The market of anti-asthmatic generic drugs progressed from 1.83 (47%) to 2.18 (23%) DDD/1000 inhabitants/day from
1999 to 2010. In 2010, inhaled glucocorticosteroids ranked first (0.83 DDD/1000 inhabitants/day), followed by inhaled
short acting beta agonists (0.73 DDD/1000 inhabitants/day). The number of brands went from 27 in 1999 to 34 in 2010,
with a generic share increasing from 55.55% to 70.59%. The number of anti-asthmatic pharmaceutical preparations
increased from 57 to 64 during the same period, of which 31 and 42 were generic preparations. In 2010, the total
cost of anti-asthmatic dugs was about 22 million euro, the generics representing 14 million euro.
Conclusion: Despite the introduction of a compulsory insurance scheme called “AMO”, that allows a refund for
69.5% of anti-asthmatic specialties marketed in Morocco, anti-asthmatic generic drug consumption remains limited.
The Moroccan market is still largely dominated by the originator drugs with still valid patents.
Keywords: Antiasthmatics; Generic drugs; Originator drugs; Drug consumption; Pricing; Compulsory health
insurance; MoroccoBackground
According to WHO estimates, there are currently 235
million asthmatic patients in the world (Organisation
mondiale de la santé (2012)). Because of its high preva-
lence, its increasing costs and the possibility to prevent
its exacerbations, asthma is a public health priority
(Delmas and Fuhrman 2010). Our knowledge of asthma
continues to grow rapidly with new concepts and ap-
proaches in the management and control of the disease
(GINA recommendations) as well as the development of
new therapeutic agents (Barnes et al. 1998), which remains
the major contributor to the global increase in asthma
care spending.* Correspondence: gh.imane@hotmail.fr
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reproduction in any medium, provided the origGeneric Drugs (GD) are associated with a reduction of
costs and according to the WHO recommendations on
rational drug use, they are considered as the best prac-
tice (Organisation mondiale de la santé (2003)).They are
at the heart of economic and social public health policies
for facilitating access of drugs to the disadvantaged
population and mastering health expenses, not only in
poor countries but also in the developed ones; thus the
increasing share of generic drug production and con-
sumption (Dussol 2009).
We conducted this study of the Moroccan pharma-
ceutical market during the period 1999-2010, with the aim
of (1) assessing whether the expiration of the Originator
Drug (OD) patent and the introduction of its GD was
followed by an increase in consumption within the same
class of anti-asthmatic drugs, (2) finding the sales share of
anti-asthmatic GD and (3) estimating the GD impact on
reducing the cost of asthma care.s is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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The study uses data from an 11 year period, long enough
to eliminate seasonality bias (Abou-Atmé et al. 2006).
The data are the number of drugs sold in private phar-
macies as reported by the Moroccan subsidiary of IMS
Health. They represent 90% of Morocco pharmaceutical
consumption. We used the WHO Anatomical Therapeutic
Chemical classification system (ATC) (WHO Collaborating
Centre for Drug Statistics Methodology 2009). The study
involved the main anti-asthmatic classes with the INNs
(International Nonproprietary Names) shown in Table 1.
The consumption data will be expressed in DDDs (Daily
Defined Doses) per 1000 inhabitants per day (DID):
DID ¼ð Number DDD=Number of days 365ð Þ½
Number of inhabitants1000Þ
The weight of the active ingredient (g) is the product
of the number of units per box by the number of boxes
sold and the dosage of the active ingredient.
ðWeight of the active ingredient gð Þ
¼ number of units per box number of boxes sold
 dosage of active ingredientÞ
The result was then divided by the DDD assigned by
the WHO Oslo Collaborating Center that is “an estimate
of the average maintenance dose per day for a drug used
for its main indication for a young adult”. A DDD is
assigned to each pharmaceutical form of a drug (WHO
Collaborating Centre for Drug Statistics Methodology
2009). For active ingredients, as well as drug combina-
tions, not included in the WHO’s ATC classification the
daily dose recommended by the VIDAL® dictionary was
used as the DDD. To have a daily consumption in DDD/
1000 inhabitants/day, we divide the number of obtained
DDD by 365 days, and by 1000 inhabitants (Sommet
et al. 2005).This unit of measurement allows compari-
sons at the international level by eliminating the diffi-
culties associated with the heterogeneity of dosageTable 1 Evolution of consumption in DID of the different fam
Class 1999
Total Antiasthmatics Antiasthmat
NS NP DID NS NP
SABA 7 9 1.95 2 2 0
LABA 2 3 0.03 —— ——
Systemic beta2- agonists 4 14 0.27 3 7 0
IC 5 9 0.71 3 4 0
LABA-IC —— —— —— —— ——
Injectable Xanthines 9 22 0.95 7 18 0
Total 27 57 3 .91 15 31
NS: Number of Specialties / NP: Number of Pharmaceutical Presentations.forms, presentations and dosages of drugs across
countries.
We used the prices from the IMS health data source
to calculate the evolution of the Moroccan Mediun
Prices (MMP) of anti-asthmatic in Moroccan dirham
(MAD) (1 euro = 11 MAD) to show the impact of
generics and new molecules on this mean price.
From a socio-economic aspect of the study, we calculated
the Median Monthly Expenditure (MME) of treatment of
different anti-asthmatic compared to the Guaranteed
Minimum Wage (GMW) (High Commission of Planning
HCP 2010) in Morocco, to highlight the part of the
consumption of these drugs in household spending.
Data were entered and analyzed using SPSS 13.0 soft-
ware. Quantitative variables were expressed as arithmetic
and weighted averages and as standard deviation.
Results
During our study period from 1999 to 2010, the total
consumption of the anti-asthmatic drugs increased from
3.91 to 14.47 DIDs (or an increase of 370%). During this
period, the evolution of the share of anti-asthmatic GD
can be divided into three phases: a first phase until 2002
where GD represented 47% in 1999 and 41% in 2001, a
second phase marked by a decrease in the mid-thirties
range (35% in 2002 and 34% in 2006) and a third phase,
after 2006, with a marked decline in GD consumption
with a share ranging from 27% in 2007 to 23% in 2010
(Figure 1).
Inhaled Corticosteroids (IC) ranked first place in GD
consumption (0.65 DID in 1999 and 0.83 in 2010 DID)
(Table 1). In this class, the total number of inhaled bude-
sonide DDDs consumed dropped from 0.02 DID (1999)
to 0.0005 DID (2010), budenoside does not have a
generic presentation. However, beclomethasonehas fully
benefited from the introduction of a generic presenta-
tion and the number of DID consumed in 2010 were
0.82 DID for the GD versus 0.19 DID for the original
drug.ilies of anti-asthmatic generic drugs in Morocco
2010
ics GD Total Antiasthmatics Antiasthmatics GD
DID (%) NS NP DID NS NP DID (%)
.4 (21.86%) 8 12 3.99 6 8 0.73 (33.48%)
—— 2 2 0.04 1 1 0.0006 (0.03%)
.15 (8.19%) 6 13 0.35 5 10 0.26 (11.92%)
.65 (35.52%) 9 13 1.13 7 8 0.83 (38.07%)
—— 4 12 3.58 2 6 0.18 (8.25%)
.63 (34.43%) 5 12 0.38 3 9 0.18 (8.25%)
1.83 (100%) 34 64 9.47 24 42 2.18 (100%)
Figure 1 Evolution of the share consumption in DDD/1000 Inhabitants/day of anti-asthmatic generic drugs in Morocco.
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1999 to 6 in 2010) and new preparations (2 in 1999 to 8
in 2010) of Short-Acting Beta Adrenergic (SABA), the
share of GD in this class has increased from 21.86% in
1999 to 33.48% in 2010 (Table 1). Salbutamol, in the
aerosolized form, remains by far the most consumed
molecule (1.29 DID for the OD versus 0.40 DID for GD
in 1999 and 3.21 DID for the OD versus 0.73 DID for all
salbutamol GD in 2010).
Formoterol and salmeterol, Long-Acting Beta Adren-
ergic drugs (LABA), show a similar evolution (0.01 DID
in 1999 versus 0.04 DID in 2010). The introduction of
this class GDs had aslight impact on the consumption of
the OD in the first two years of its launch to stagnate
from 2007 to 0.04 DID, although its share (GD) in sales
(€) presented a discount of 97.42% (from €76 920 in 2006
to €1 985 in 2010) (Table 2).
GDs of the injectable xanthenes class were marked by
a decline in consumption from 0.63 DID in 1999 to
0.18 DID in 2010 (Table 1). Unlike the only GD of theo-
phylline marketed in Morocco (Xanthium LP®) which
showed a marked decrease of 33.50% in volume and
69.60% in value. The generic association diprophylline-
timonium (Timozyl®) kept its market share during the
study period.
For the LABA-IC fixed combinations, the consump-
tion of the fluticasone-salmeterol has changed substan-
tially. The other association, budesonide-formoterol, that
had no generic product, showed a significant increase in
consumption (Tables 1 and 2).
Total GD saleswent from €6 million in 1999 to €14
million in 2010, representing 71.87% and 63.50% respect-
ively of the anti-asthmatic market revenues (Table 2).
Beclomethasone, the first molecule of the IC class to have
a generic on the Moroccan market showed an increase in
from €4 million in 1999 to €8 million in 2010, totaling
more than half of the anti-asthmatic medications sales.
The other half was represented mainly by the SABA class,especially salbutamol. In contrast, the xanthine sales
regressed by 54.4% (from €919,817 in 1999 to €419,381 in
2010).
As for the MME, the ratio MME/GMW of anti-
asthmatic classes with at least one GD on the Moroccan
market decreased gradually between 1999 and 2010, ex-
cept for the xanthines (Table 3).
Regarding research ethics, this study is not an experi-
mental research nor carried on humans. It also falls
outside of the guidelines of health research ethics in
Morocco. The data used for this study is from the
Moroccan subsidiary of IMS Health.Discussion
Medications are an important component of health care
cost. In Morocco, they reached more than 40% of the
total health cost in 2007, compared to 18% on average in
OECD countries (Commission des Finances et du Dével-
oppement Economique de la Chambre des Représentants
2009). In Europe, GD prescription shares were around
50% in 2005, with 40% in France, 52% in Germany and 57%
in the UK. In United States, the generic market share is
more important as it is more than 60% (Zambrowski
2001; Doctisimo 2013; IMS health 2005).
In Morocco, with a volume of 77 million boxes and
revenues of €200 million, GDs represented 27% of the
pharmaceutical market in 2009. The hospital share of
GDs in volume is much higher (80-90%) as the drugs
are acquired by public tenders from the lowest bidder.
In 2010, GD shares in private pharmacies reached 27.6%
in volume and 28.3% in value (Doctisimo 2013; Associ-
ation Marocaine de l’industrie Pharmaceutique AMIP
2010). Indeed, in 9 years, the use of GD has increased by
6.45 percentage points, from 19.15% in 2001 to 27.6%
in 2010, or 0.72% per year (Association Marocaine de
l’industrie Pharmaceutique AMIP 2010; Conseil de la
concurrence and S.I.S consultant 2009).
Table 2 Evolution of the sales share of anti-asthmatics GD in turnover and percentage consumption of all
anti-asthmatics drugs
Class/INN ATC 1999 2006 2009
Sales (€) % Sales (€) % Sales (€) %
SABA
Salbutamol R03AC02 834 612 12.53 1 446 152 19.43 1 631 991 89,73
Terbutaline R03AC03 —— —— —— —— —— ——
Fenoterol R03AC04 —— —— —— —— —— ——
Pirbuterol R03AC08 —— —— —— —— —— ——
Orciprenaline R03AB03 —— —— —— —— —— ——
Systemic Beta 2 agonists
Salbutamol R03CC02 498 787 45,62 913 079 64,44 1 071 750 68,88
Terbutaline R03CC03 287 261 100 117 459 100 103 982 100
LABA
Formeterol R03AC12 —— —— 76 920 13.18 1 985 0.33
Salmeterol R03AC13 —— —— —— —— —— ——
LABA-IC
Fluticasone + Salmeterol R03AK06 —— —— —— —— 2 038 025 63.36
Budesonide + Formeterol R03AK07 —— —— —— —— —— ——
IC
Beclomethasone R03BA01 4 077 376 100 7 239 239 94.44 8 908 178 92.62
Budesonide R03BA02 —— —— —— —— —— ——
Fluticasone R03BA05 —— —— —— —— 58 290 5.74
Injectable Xanthines
Theophylline R03DA04 673 360 59.83 274 693 43.85 204 994 39.81
Diprophylline + Tiemonium iodure R03DA51 246 457 100 246 385 100 214 387 100
Total 6 617 853 71.87% 10 313 927 62.84% 14 233 582 63.50%
——: No GD.
1 € = 11 MAD.
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of the market for the top four pharmaceutical companies
among 30 (competition ratios: Cr4 = 45 Cr8 = 72 and
Cr20 = 99). Global forecasts estimate that the proportion
of GD for respiratory diseases should increase signifi-
cantly (Chidambaram 2012).
In this study, we analyzed the evolution of the anti-
asthmatic GD market shares in volume and value and
identified factors influencingits evolution. From 1999 to
2010, the consumption of all classes of anti-asthmatic
drugs showed a clear evolution. Indeed, this 11 year
period was marked by three major events:
- A high prevalence of respiratory diseases requiring
treatment with anti-asthmatic drugs. Asthma and
Chronic Obstructive Pulmonary Disease (COPD) are
reflecting the high indices of pollution of major and
industrialized cities (Rabat, Asthma: 6.6%; Casablanca,
Asthma: 12.1% and Chronic Bronchitis: 14%) (Nafti et al.
2009; Chan-Yeung et al. 2004). Pollution represents oneof the most important risk factors for asthma (Puddu
and Tafforeau 2003), and explains its significant increase
in industrialized countries in recent decades, where the
prevalence is about 10% (Holgate 1999);
- An evolution of the socioeconomic and socio-cultural
level of the Moroccan population with an accentuation
of the rural exodus and uncontrolled urbanization
(Haut Commissariat au Plan HCP 2010). However, this
allowed more access to health care structures and
pharmaceuticals products;
- The implementation of a Compulsory Health
Insurance (named AMO) in 2006 increased the
percentage of the population covered by this scheme
(Agence Nationale de l’Assurance Maladie ANAM
2011). Thus patients could afford to buy the expensive
new molecules, including the fixed association LABA-IC,
as they were reimbursed.
Despite this, the average drug consumption per
capita remains low. Encouragement of prescription
Table 3 Evolution of the monthly average cost of anti-asthmatic generic drugs compared to guaranteed minimum
wage Moroccan asthma
Class/INN ATC 1999 2006 2010
MME IQR MME/GMW MME IQR MME/GMW MME IQR MME/GMW
SABA
Salbutamol R03AC02 6.02 5.85-6.19 0.04 5.64 5.53-5,81 0.03 5.42 4.38-5.64 0.03
Terbutaline R03AC03 —— —— —— —— —— —— —— —— ——
Fenoterol R03AC04 —— —— —— —— —— —— —— —— ——
Pirbuterol R03AC08 —— —— —— —— —— —— —— —— ——
Orciprenaline R03AB03 —— —— —— —— —— —— —— —— ——
Systemic Beta 2 agonists
Salbutamol R03CC02 13.33 10.13-22.78 0,09 14.64 10.68-24.58 0.08 12.14 8.05-15.76 0.06
Terbutaline R03CC03 25.34 15.25-79.45 0,17 12.25 11.48-21.49 0.07 13.05 —— 0.07
LABA
Formeterol R03AC12 —— —— —— 5.53 —— 0.03 8.53 —— 0.04
Salmeterol R03AC13 —— —— —— —— —— —— —— —— ——
LABA-IC
Fluticasone + Salmeterol R03AK06 —— —— —— —— —— —— —— —— ——
Budesonide + Formeterol R03AK07 —— —— —— —— —— —— 17.65 6.76-26.73 0.09
IC
Beclomethasone R03BA01 10.95 8.36-15.30 0,07 5.90 4.02-11.85 0.03 5.90 4.20-12.55 0.03
Budesonide R03BA02 —— —— —— —— —— —— —— —— ——
Fluticasone R03BA05 —— —— —— —— —— —— 17.14 15.76-18.53 0.09
Injectable Xanthines
Theophylline R03DA04 5.29 4.15-9.88 0,04 3.92 3.47-4.88 0.02 4.19 3.62-4.95 0.02
Diprophylline + Tiemonium iodure R03DA51 13.42 13.25-14.54 0,09 12.79 12.64-13.90 0.07 12.79 12.64-13.90 0.07
——: No GD.
MME: Median Monthly Expenditure; IQR: InterQuartile Ranges.
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allowing the Moroccan population access to affordable
drugs. It should be associated with a generalization of
the compulsory health insurance and a revision of the
Moroccan system of drug pricing (Association Maro-
caine de l’Industrie Pharmaceutique AMIP 2008). In
our study, the evolution of anti-asthmatic GD con-
sumption is not constant and is not the same for all
molecules. The majority of IC class consumption, both
in volume and in value, is represented by beclometha-
sone since glucocorticoid therapy is indicated as the
first-line treatment of symptomatic asthma (Pujet and
Evano-Celli 1995; High Commission of Planning-HCP
2004; Groupe suisse de travail de pneumologie pédia-
trique SAPP 2004; Coignard et al. 2001).
Usually, when a molecule loses its patent, expenditures
are shifted towards the GDs. It was not the case for
salbutamol, which is prescribed, according to GINA, as atreatment for asthma attacks (Global Initiative for Asthma
GINA 2011). In 2006, salbutamol represented 50.44% of
anti-asthmatic consumption in Morocco (Ghanname et al.
2012). In the United Kingdom it was 58% and in Spain 51%.
The GDs of salbutamol had only a slight evolution dur-
ing this decade. And the originator product, Ventolin®,
ranked 6th of the top-selling drugs in value and 17th in
volume (Association Marocaine de l’industrie Pharmaceu-
tique AMIP 2010), representing 10% of GSK’s revenues
(Conseil de la concurrence and S.I.S consultant 2009).
Its price of €5.11 is aligned with its original price in
France (Vidal-Eurekasante 2013) while its cheapest gen-
eric, Magistral®, costs €3.64. Despite the its patent expir-
ation in September 1987, Ventolin® sales remained high
because the physicians kept prescribing that brand and
the patients used it for self-medication.
In Tunisia, a neighboring country with about the same
level of development but a better health system on
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(-56% of the Moroccan Public Price) (Pharmacie Centrale
de Tunisie 2013a). In only three years (2006 to 2008)
Moroccan patients paid about 19 million Euro more than
Tunisians for Ventolin®, according to the findings of the
Finance Committee of the House of Representatives in his
informative mission on drug prices in Morocco (Commis-
sion des Finances et du Développement Economique de la
Chambre des Représentants 2009). This price difference
cannot be explained by the size of the market, nor the
VAT nor customs duties or by the distribution margins,
but by a system of centralized purchasing of imported
drugs from all public and private companies via the Cen-
tral Pharmacy of Tunisia and its bargaining power as rec-
ognized by WHO (Conseil de la concurrence and S.I.S
consultant 2009). The same system is also adopted by
New Zealand that gave it the label of promising model
in studies on drug prices worldwide.
The fixed association LABA-IC, fluticasone-salmeterol,
marketed by GSK in 2002 as imported SeretideDiskus®
has become one of the main drug prescribed because it is
more effective (Sbrewsburyss and Britton 2000). This was
at the expense of the all classes of anti-asthmatic GDs
which went from 46% in 2001 to 33% in 2005.
SeretideDiskus® was protected by another additional
few years protection, until September 2013, thanks to
“Data Protection” that extends the life of the patent
and creates a new barrier to GD access and is con-
sidered a “crime” against the pharmaceutical compe-
tition (Narendranath 2004; Boulet 2003; Correa 2002;
GalaxoSmithKline GSK plc 2002) since it is reduced
to the OD only. In 2007, Cooper Pharma introduced
Saflu® PMDI with a two-third price reduction, as it
is the rule for the first generic. Despite this price
difference, the SeretideDiskus® has kept prescribers and
patients favors because it is thanks to its easy to use,
allowing a good compliance (Khassawneh et al. 2008). In
addition, the PMDI requiresthe use of a spacer device in
children and the elderly which generates an additional
treatment cost.
It was expected that the marketing of the second
fixed combination containing budesonide and formeterol
(Symbicort Turbuhaler®, AstraZeneca), protected until
december 2012, would be accompanied by lower prices
due to the competition, but its price was twice the
SeretideDiskus® price. The multiplication of devices has in-
troduced other parameters (deposited dose in the bronchi,
inspiration force etc.) to prove the effectiveness and deter-
mine the price of each specialty (Khassawneh et al. 2008).
No generic of this fixed dose combination is yet marketed.
It is a paradox, that in countries with low purchas-
ing power, such as Morocco, the most expensive
products are the most sold. The causes lie in the in-
adequacy of policies to promote the GD and theireffectiveness to fight strategies put in place by man-
ufacturers of ODs.
The best indicator of these strategies success or failure
is the part of GDs in the volume of sold drugs. The anti-
asthmatic GDs have not had the expected success; their
share did not exceed 23% in 2010.
In its 2004 study of Moroccan drug prices, WHO,
quoted in the report of the parliamentary mission (Com-
mission des Finances et du Développement Economique
de la Chambre des Représentants 2009), said that “The
predominance of branded drugs in Morocco may be ex-
plained by the pricing policy which is biased in favor of
the most expensive products”. The manufacturer of the
original brand receives, after the expiry of the patent, an
additional gain by high profit margins, allowing him to
easily invest in advertising campaigns to increase sales of
their product and creating a vicious circle at the expense
of consumers. A doubt about the quality and efficacy
of GDs is created and maintained by the originator
manufacturers in the mind of physicians and patients
(although officially they say otherwise).
In 2010, a new methodology for pricing the originator
drugs was introduced by the Moroccan Ministry Of
Health. Itis based on the benchmark of wholesale price,
excluding taxes (Gross PPD) in selected countries, in-
cluding France, Belgium, Spain, Portugal, Greece, Turkey
and Saudi Arabia. The set price for any new innovative
drug will be the lowest price in these 7 countries. AMIP,
the Moroccan pharmaceutical industry association, in its
March 2010 document (Association Marocaine de l’in-
dustrie Pharmaceutique AMIP 2010), proposes a system-
atic benchmarking with comparable countries that have
managed to get low prices (OD or GD), and whose prices
are publicly available, such as Tunisia, Egypt, South Africa
and some European countries, and use publicly available
databases of essential drugs established and updated regu-
larly by WHO.AMIP proposes also not make a distinction
in the pricing procedure between originator drugs whose
patent has expired and generic drugs. Their prediction
would be an increase of GD consumption from 29% in
2010 to over 50% by 2015.
Despite some efforts, manufacturers of GDs have not
yet managed to thwart the strategy of originator drug
manufacturers by raising physicians and patients’ confi-
dence in GDs. To overcome their reluctance, among
others, a massive communication campaign aimed at
the public and the professionals, especially prescribers,
should be undertaken. The pharmacist should have the
right of substitution while keeping the same benefit mar-
gin on the GD as on thecorresponding OD. The health
insurance reimbursement policy based on the cheapest
generic drug will push originator drug manufacturers to
lower their prices as patients become more cost con-
scious (Zambrowski 2001).
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other Long Term Disease (LTD), are generally economically
burdensome. In fact, they require follow up and some regu-
lar treatments for long periods, if not for life. In the absence
of health insurance coverage, the situation becomes un-
bearable for patients, especially the poorest.
France has one of the world’s best health insurance
systems. It covers 100% of its population. In Tunisia, 80%
of the population is practically covered while in Morocco,
two thirds of its citizens remain still excluded from any
diseaseinsurance system (Caisse Nationale de Sécurité
Sociale CNSS 2011).
In 2006, Morocco launched the compulsory health in-
surance (AMO, managed by the CNSS and CNOPS) and
RAMED schemes. According to the CNOPS data, LTD
drug expenditures increased by 40% each year, reaching
over €32 million in 2008 (Conseil de la concurrence and
S.I.S consultant 2009). They refund 100% of the drug
costs for these 41 diseases.
In 2009, more than 2 500 drugs were refundable (about
60% of the drug present in the Moroccan market). It
should be recalled that 69.5% among anti-asthmatics
specialties are refundable.
The Morocco Competition Council analysis of the
cost evolution of generics acquired by the CNOPS
showed a glaringdisparity when compared to the origina-
tors (Conseil de la concurrence and S.I.S consultant 2009).
In value, GD accounted for only 7% of the CNOPS
pharmacy spending. In volume, they represented nearly
30% of drug sales in pharmacies and nearly 90% of the
Ministry of Health purchases. Most drugs reimbursed by
the CNOPS are called “innovative” (70%) and do not
have GDs. But even for those with generics, physicians’
prescriptions are dominated by originator drugs.
The low percentage of GDs purchased by the CNOPS
pharmacy can be explained by the scarcity or the ab-
sence of GDs for some LTD in one hand, and by the
limited use of these GDs when they are available.
To ensure the viability of the AMO, the informative
mission on the drug pricing in Morocco suggests that
the refund shall be made on the basis of a Reference
Price. A drug whose price is higher than the reference
price by more than 30% should not be reimbursed. This
selective reimbursement will end the uncontrolled pro-
liferation of GDs and exclude immediately from refund
all the expensive medications with a generic on the
market. If these measures are accompanied by an infor-
mation campaign targeting prescribers, so that patients
are not harmed, they should result in the promotion of
GDs and in reductions of more than 40% of the price of
these drugs. The mission suggests also that reimburs-
able drugs by AMO should have a visible distinctive
label on their packaging to guide the prescribers and
patients.This decade-long study on the consumption profile of
anti-asthmatic GDs in Morocco has some limitations,
including the method used to calculate consumption.
The DDD is an approximate measurement unit and do
not necessarily reflect the daily dose consumed, it does
not also take into account the severity of the asthma
(Coignard et al. 2001). In addition, the data contain no
information on the observance of the treatment, and
therefore we cannot assume that the marketed drug had
been taken by the patients.
Conclusion
Contrary to expectations and despite the introduction of
the AMO in 2006 and the involvement of the state in pro-
moting GDs, the share anti-asthmatic generics remained
limited. This is due to several factors: ones inherent to the
generic drug situation in Morocco and the others specific
to this class of therapeutics - sociocultural context,
traditional healing, difficulty using the device, patients
not aware of the gravity of their disease.
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